Selective mGluR1 antagonist EMQMCM inhibits the kainate-induced excitotoxicity in primary neuronal cultures and in the rat hippocampus

Neurotoxicity Research

Volumn 21, Issue 4, 2012, Pages 379-392

  Śmialowska, Maria ^a   Golembiowska, Krystyna ^b   Kajta, Malgorzata ^b   Zieba, Barbara ^a   Dziubina, Anna ^b   Domin, Helena ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

EMQMCM; Excitotoxicity; Kainic acid; Metabotropic glutamate receptors; MGlu1 antagonist; Neuroprotection

Indexed keywords

(3 ETHYL 2 METHYL QUINOLIN 6 YL)(4 METHOXYCYCLOHEXYL)METHANONE METHANESULFONE; 4 AMINOBUTYRIC ACID; CASPASE 3; GLUTAMIC ACID; JNJ 16567983; KAINIC ACID; LACTATE DEHYDROGENASE; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN NERVE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; EMBRYO; EXCITOTOXICITY; EXTRACELLULAR SPACE; GABAERGIC TRANSMISSION; GLUTAMATE RELEASE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; CASPASE 3; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HIPPOCAMPUS; KAINIC ACID; L-LACTATE DEHYDROGENASE; MALE; MICE; MICROINJECTIONS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PRIMARY CELL CULTURE; QUINOLINES; RATS; RATS, WISTAR;

RATTUS;

EID: 84861455558     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-011-9293-4     Document Type: Article

References (75)

1. Allen JW, Knoblach SM, Faden AI (2000) Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro. Cell Death Differ 7:470-476 (Pubitemid 30255715)
2. Bao WL, Williams AJ, Faden AI, Tortella FC (2001) Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res 922:173-179 (Pubitemid 34017477)
3. Battaglia G, Bruno V, Pisani A, Centonie D, Catania MV, Calabresi P, Nicoletti F (2001) Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing GABAergic transmission. Mol Cell Neurosci 17:1071-1083 (Pubitemid 32641875)
4. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY (2007) Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 17:172-179 (Pubitemid 44779190)
5. Brewer GJ (1995) Serum-free B27/neurobasal medium supports differentiated growth of neurones from the striatum, substantia nigra, septum, cerebral cortex, cerebellum and dentate gyrus. J Neurosci Res 42:674-683
6. Bruno V, Copani A, Knöpfel T, Kuhn R, Casabona G, Dell'Albani P, Condorelli DF, Nicoletti F (1995) Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neuropharmacology 34:1089-1098
7. Bruno V, Copani A, Bonanno L, Knoepfel T, Kuhn R, Roberts PJ, Nicoletti F (1996) Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur J Pharmacol 310:61-66 (Pubitemid 26284257)
8. Bruno V, Sureda FX, Storto M, Casabona G, Caruso A, Knopfel T, Kuhn R, Nicoletti F (1997) The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J Neurosci 17:1891-1897 (Pubitemid 27106748)
9. Bruno V, Battaglia G, Kingston A, O'Neill MJ, Catania MV, Di Grezia R, Nicoletti F (1999) Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (?)-2-methyl-4-carboxyphenylglycine (LY367385): Comparison with LY 357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology 38:199-207 (Pubitemid 29073539)
10. Bruno V, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D, Gasparini F, Kuhn R, Nicoletti F, Flor PJ (2000) Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39:2223-2230 (Pubitemid 30642765)
11. Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, Nicoletti F (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21:1013-1033 (Pubitemid 32823739)
12. Byrnes KR, Loane DJ, Faden AI (2009) Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurotherapeutics 6:94-107
13. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634
14. Choi DW (1994) Glutamate receptors and the induction of excitotoxic neuronal death. Prog Brain Res 100:47-51 (Pubitemid 24253084)
15. Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237 (Pubitemid 27238875)
16. Copani A, Bruno VM, Barresi V, Battaglia G, Condorelli DF, Nicoletti F (1995) Activation of metabotropic glutamate receptors prevents neuronal apoptosis in culture. J Neurochem 64:101-108
17. Coyle JT (1983) Neurotoxic action of kainic acid. J Neurochem 41:1-11 (Pubitemid 13064890)
18. Cozzi A, Meli E, Carlà V, Pellicciari R, Moroni F, Pellegrini- Giampietro DE (2002) Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: A mechanism for the attenuation of post-ischemic injury and epileptiform activity? Neuropharmacology 43:119-130 (Pubitemid 35247600)
19. Danysz W, Parsons CG (1998) Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications. Pharmacol Rev 50:597-664 (Pubitemid 29028813)
20. de Novellis V, Marabese I, Palazzo E, Rossi F, Berrino L, Rodella L, Bianchi R, Rossi F, Maione S (2003) Group I metabotropic glutamate receptors modulate glutamate and gamma-aminobutyric acid release in the periaqueductal grey of rats. Eur J Pharmacol 462:73-81 (Pubitemid 36183737)
21. Domin H, Kajta M, Smialowska M (2006) Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures. Pharmacol Rep 58:846-858 (Pubitemid 46117736)
22. Domin H, Zieba B, Golembiowska K, Kowalska M, Dziubina A, Śmialowska M (2010) Neuroprotective potential of mGluR5 antagonist MTEP: Effects on kainate-induced excitotoxicity in the rat hippocampus. Pharmacol Rep 62:1051-1061
23. Faden AI, O'Leary DM, Fan L, Bao W, Mullis PGM, Movsesyan VA (2001) Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improves outcome after brain trauma. Exp Neurol 167:435-444 (Pubitemid 32150901)
24. Ferkany JW, Coyle JT (1983) Kainic acid selectively stimulates the release of endogenous excitatory acidic amino acids. J Pharmacol Exp Ther 225:399-406 (Pubitemid 13091231)
25. Ferkany JW, Zaczek R, Coyle JT (1982) Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. Nature 298:757-759 (Pubitemid 12041373)
26. Ferraguti F, Crepaldi L, Nicoletti F (2008) Metabotropic glutamate 1 receptor: Current concepts and perspectives. Pharmacol Rev 60:536-581
27. Flor PJ, Battaglia G, Nicoletti F, Gasparini F, Bruno V (2002) Neuroprotective activity of metabotropic glutamate receptor ligands. Adv Exp Med Biol 513:197-223 (Pubitemid 36332408)
28. Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, Laurie D, Sommer B, Varney MA, Hess SD, Johnson EC, Kuhn R, Urwyler S, Sauer D, Portet C, Schmutz M, Nicoletti F, Flor PJ (1999) (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther 289:1678-1687 (Pubitemid 29246706)
29. Golembiowska K, Dziubina A (2004a) Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum. Brain Res 998:208-217 (Pubitemid 38125062)
30. Golembiowska K, Dziubina A (2004b) Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopaminedenervated rats. Neuropharmacology 47:414-426 (Pubitemid 38953233)
31. Gravius A, Pietraszek M, Schäfer D, Schmidt WJ, Danysz W (2005) Effects of mGlu1 and mGlu5 receptor antagonists on negatively reinforced learning. Behav Pharmacol 16:113-121 (Pubitemid 40477538)
32. Gundersen HJ, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229-263
33. Ikonomidou C, Turski L (2002) Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 1:383-386 (Pubitemid 37159164)
34. Kajta M, Lasoń W (2000) Oestrogen effects on kainate-induced toxicity in primary cultures of rat cortical neurons. Acta Neurobiol Exp (Wars) 60:365-369 (Pubitemid 30659912)
35. Kajta M, Budziszewska B, Lasoń W (1999) Allopregnanolone attenuates kainate-induced toxicity in primary cortical neurons and PC12 neuronal cells. Pol J Pharmacol 51:531-534 (Pubitemid 30052675)
36. Kajta M, Lasoń W, Kupiec T (2004) Effects of estrone on N-methyl- D-aspartic acid- and staurosporine-induced changes in caspase-3- like protease activity and lactate dehydrogenase-release: Time and tissue-dependent effects in neuronal cultures. Neuroscience 123:515-526 (Pubitemid 38032927)
37. Kajta M, Trotter A, Lasoń W, Beyer C (2005) Effect of NMDA on staurosporine-induced activation of caspase-3 and LDH release in mouse neocortical and hippocampal cells. Brain Res Dev Brain Res 160:40-52 (Pubitemid 41512805)
38. Kajta M, Domin H, Grynkiewicz G, Lason W (2007) Genistein inhibits glutamate-induced apoptotic processes in primary neuronal cell cultures: An involvement of aryl hydrocarbon receptor and estrogen receptor/glycogen synthase kinase-3beta intracellular signaling pathway. Neuroscience 145:592-604 (Pubitemid 46341646)
39. Knecht R, Chang JY (1986) Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino) azobenzenesulfonyl chloride. Anal Chem 58:2375-2379
40. Kohara A, Takahashi M, Yatsugi S, Tamura S, Shitaka Y, Hayashibe S, Kawabata S, Okada M (2008) Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res 1191:168-179
41. Kotlinska J, Bochenski M (2008) The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Eur J Pharmacol 598:57-63
42. Lea PM IV, Movsesyan VA, Faden AI (2005) Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br J Pharmacol 145:527-534 (Pubitemid 40966282)
43. Lesage ASJ, Bischoff F, Van Beijsterveldt L, Meert T, Steckler T, Ashton D (2002) Novel, centrally active mGlu1 antagonists: In vitro and in vivo pharmacology. Neuropharmacology 43:295
44. Liu W, Liu R, Chun JT, Bi R, Hoe W, Schreiber SS, Baudry M (2001) Kainate excitotoxicity in organotypic hippocampal slice cultures: Evidence for multiple apoptotic pathways. Brain Res 916:239-248 (Pubitemid 32971925)
45. Makarewicz D, Duszczyk M, Gadamski R, Danysz W, Lazarewicz JW (2006) Neuroprotective potential of group I metabotropic glutamate receptor antagonists in two ischemic models. Neurochem Int 48:485-490
46. Mazzone GL, Nistri A (2011) Delayed neuroprotection by riluzole against excitotoxic damage evoked by kainate on rat organotypic spinal cord cultures. Neuroscience. doi: 10.1016/j.neuroscience. 2011.06.013
47. Mazzone GL, Margaryan G, Kuzhandaivel A, Nasrabady SE, Mladinic M, Nistri A (2010) Kainate-induced delayed onset of excitotoxicity with functional loss unrelated to the extent of neuronal damage in the in vitro spinal cord. Neuroscience 168:451-462
48. McGeer EG, McGeer PL, Singh K (1978) Kainate-induced degeneration of neostriatal neurons: Dependency upon corticostriatal tract. Brain Res 139:381-383 (Pubitemid 8248268)
49. Muir KW, Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513
50. Murotomi K, Takagi N, Takayanagi G, Ono M, Takeo S, Tanonaka K (2008) mGluR1 antagonist decreases tyrosine phosphorylation on NMDA receptor and attenuates infarct size after transient focal cerebral ischemia. J Neurochem 105:1625-1634 (Pubitemid 351678489)
51. Musante V, Neri E, Feligioni M, Puliti A, Pedrazzi M, Conti V, Usai C, Diaspro A, Ravazzolo R, Henley JM, Battaglia G, Pittaluga A (2008) Presynaptic mGlu1 and mGlu5 autoreceptors facilitate glutamate exocytosis from mouse cortical nerve endings. Neuropharmacology 55:474-482
52. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA et al (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37-43
53. Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T (1996) Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders? Trends Neurosci 19:267-271 (Pubitemid 26000672)
54. Nicoletti F, Bruno V, Catania MV, Battaglia G, Copani A, Barbagallo G, Ceña V, Sanchez-Prieto J, Spano PF, Pizzi M (1999) Group-I metabotropic glutamate receptors: Hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology 38:1477-1484 (Pubitemid 29457729)
55. Olney JW (1978) Neurotoxicity of excitatory amino acids. In: McGeer EG, Olney JW, McGeer PL (eds) Kainic acid as a tool in neurobiology. Raven Press, New York, pp 95-112
56. Olney JW, Ishimaru MJ (1999) Excitotoxic cell death. In: Koliatsos VE, Ratan RR (eds) Cell death and diseases in the nervous system. Humana Press, Totowa, pp 197-220
57. Ossowska K, Wardas J, Ś mialowska M, Kuter K, Lenda T, Wierońska JM, Zieba B, Nowak P, Dabrowska J, Bortel A, Kwieciński A, Wolfarth S (2005) A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: An animal model of preclinical stages of Parkinson's disease Eur J Neurosci 22:1294-1304 (Pubitemid 41442403)
58. Ossowska K, Ś mialowska M, Kuter K, Wierońska J, Zieba B, Wardas J, Nowak P, Dabrowska J, Bortel A, Biedka I, Schulze G, Rommelspacher H (2006) Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: Implications for Parkinson's disease. Neuroscience 141:2155-2165 (Pubitemid 44233146)
59. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego
60. Pellegrini-Giampietro DE, Peruginelli F, Meli E, Cozzi A, Albani- Torregrossa S, Pellicciari R, Moroni F (1999) Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: Time-course and mechanisms. Neuropharmacology 38:1607-1619 (Pubitemid 29457742)
61. Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Waslowska A, Plaźnik A, Bespalov AY, Danysz W (2005) Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 514:25-34 (Pubitemid 40692760)
62. Pin JP, Duvoisin R (1995) The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 34:1-26
63. Popoli P, Pintor A, Tebano MT, Frank C, Pepponi R, Nazzicone V, Grieco R, Pèzzola A, Reggio R, Minghetti L, De Berardinis MA, Martire A, Potenza RL, Domenici MR, Massotti M (2004) Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: Involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity. J Neurochem 89:1479-1489 (Pubitemid 38802669)
64. Rao AM, Hatcher JF, Dempsey RJ (2000) Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neurosci Lett 293:1-4
65. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, Flor PJ, Neki A, Abe T, Nakanishi S, Mizuno N (1997) Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 17:7503-7522 (Pubitemid 27413281)
66. Shih YH, Wu SL, Chiou WF, Ku HH, Ko TL, Fu YS (2002) Protective effects of tetramethylpyrazine on kainate-induced excitotoxicity in hippocampal culture. Neuroreport 13:515-519
67. Shih YH, Chein YC, Wang JY, Fu YS (2004) Ursolic acid protects hippocampal neurons against kainate-induced excitotoxicity in rats. Neurosci Lett 362:136-140
68. Siniscalco D, Giordano C, Fuccio C, Luongo L, Ferraraccio F, Rossi F, de Novellis V, Roth KA, Maione S (2008) Involvement of subtype 1 metabotropic glutamate receptors in apoptosis and caspase-7 over-expression in spinal cord of neuropathic rats. Pharmacol Res 57:223-233
69. Śmialowska M, Wierońska JM, Szewczyk B (2003) Neuroprotective effect of NPY on kainate neurotoxicity in the hippocampus. Pol J Pharmacol 55:979-986 (Pubitemid 38128933)
70. Śmialowska M, Domin H, Zieba B, Koźniewska E, Michalik R, Piotrowski P, Kajta M (2009) Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides 43:235-249
71. Speed HE, Dobrunz LE (2008) Developmental decrease in short-term facilitation at Schaffer collateral synapses in hippocampus is mGluR1 sensitive. J Neurophysiol 99:799-813 (Pubitemid 351253236)
72. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: Behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277 (Pubitemid 36900596)
73. Szydlowska K, Kaminska B, Baude A, Parsons CG, Danysz W (2007) Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. Eur J Pharmacol 554:18-29 (Pubitemid 44820044)
74. Wang Q, Yu S, Simonyi A, Sun GY, Sun AY (2005) Kainic acidmediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol 31:3-16 (Pubitemid 41271190)
75. Watkins JC, Evans RH (1981) Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol 21:165-204